Renal carcinoma

Liguisticum wallichii inhibits renal carcinoma progression by downregulating UBE3A and through suppression of NF-κB signaling

J. S. Wu, Zhang, P. M., Sun, L. J., Liu, X. Z., Wu, J. S., Zhang, P. M., Sun, L. J., Liu, X. Z., Wu, J. S., Zhang, P. M., Sun, L. J., and Liu, X. Z., “Liguisticum wallichii inhibits renal carcinoma progression by downregulating UBE3A and through suppression of NF-κB signaling”, vol. 15, no. 4, p. -, 2016.

INTRODUCTION

Lack of clinical significance of the ImmuKnowTM-Cylex assay for the detection of cellular immune function in patients with renal cell carcinoma

K. Zheng, Zhang, J. P., Tan, J. M., Wu, W. Z., Yang, S. L., and Ke, D. D., “Lack of clinical significance of the ImmuKnowTM-Cylex assay for the detection of cellular immune function in patients with renal cell carcinoma”, vol. 14, pp. 11543-11550, 2015.

This study aimed to explore the clinical value of the CD4+ T cell ATP levels in patients with renal cell carcinoma through the application of the ImmuKnowTM-Cylex® assay. We recruited 104 patients with renal cancer who had undergone surgery at Fuzhou General Hospital from March 2009 to June 2012, and were subsequently treated by dendritic cell and cytokine-induced killer cell bio-therapy or interferon-α therapy.

Subscribe to Renal carcinoma